Chugai Pharmaceutical Co., Ltd

4519

JP3519400000

Pharmaceuticals

Delayed Japan Exchange Other stock markets 01:30:00 2025-01-10 am EST			5-day change	1st Jan Change
6,737.00 ^JPY	-3.12%		-3.74%	-3.74%

Jan. 08	Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris' AraLinQ? technology	CI
Dec. 19	Chiome Bioscience Extends Master Services Agreement with Chugai Pharmaceutical	MT

Chugai Pharmaceutical - Verastem Oncology's Announcement Regarding Avutometinib

November 04, 2024 at 09:26 am EST

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Verastem Oncology issued a press release on October 31 about completion of rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for avutometinib plus defactinib as a treatment for recurrent KRAS mutant low-grade serous ovarian cancer.

Avutometinib, a RAF/MEK clamp, was created by Chugai, and its clinical development is being conducted by Verastem Oncology

Contact:

Hideki Sato

Tel: +81-3-3273-0881

Email: pr@chugai-pharm.co.jp

Takayuki Sakurai

Tel: +81-3-3273-0554

Email: ir@chugai-pharm.co.jp

Latest news about Chugai Pharmaceutical Co., Ltd

Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris' AraLinQ? technology	Jan. 08	CI
Chiome Bioscience Extends Master Services Agreement with Chugai Pharmaceutical	Dec. 18	MT
Jefferies Downgrades Chugai Pharmaceutical to Hold From Buy, Adjusts Price Target to 7,700 Yen From 7,100 Yen	24-10-30	MT
Musk on top of Wall Street	24-10-25
Chugai Pharmaceutical's Nine-Month Profit Balloons 26%	24-10-25	MT
Chugai Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the Financial Year Ending December 31, 2024	24-10-25	CI
Jefferies Adjusts Chugai Pharmaceutical's Price Target to 7,100 Yen From 7,000 Yen, Keeps at Buy	24-07-26	MT
Chugai Pharmaceutical Co., Ltd., Q2 2024 Earnings Call, Jul 25, 2024	24-07-25
Maruishi Pharmaceutical Co.,Ltd. agreed to acquire MONILAC Business of Chugai Pharmaceutical Co., Ltd.	24-07-21	CI
Financials lift Japanese shares on rate-hike speculation	24-07-01	RE
Japan's Nikkei ends choppy session on stronger note	24-06-24	RE
Japan's Nikkei squeezes out gains in choppy session	24-06-23	RE
Japan's Nikkei rises on US stocks, heavyweight chip shares	24-06-10	RE
Tech stocks lift Japan's Nikkei on boost from Nvidia's robust outlook	24-05-22	RE
Japan's Nikkei drifts sideways as more earnings, US CPI awaited	24-05-13	RE
Chugai Pharmaceutical Allots 594 Million Yen Worth of Shares as Restricted Stock Compensation	24-05-01	MT
Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%	24-04-25	MT
Chugai Pharmaceutical's Profit Slightly Up in Q1	24-04-24	MT
Japan's Nikkei slips on caution ahead of US inflation data	24-04-09	RE
Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation	24-03-29	MT
Roche's Chugai Wins Japanese Approval for Piasky Injection	24-03-27	MT
Jefferies Adjusts Chugai’s Price Target to 7,000 Yen From 6,200 Yen, Keeps at Buy	24-03-04	MT
Interest Rates, Central Bank Outlooks Churn Asian Stock Markets	24-02-26	MT
Nikkei extends record rally on pharma boost	24-02-25	RE
Nikkei hits record high as index heavyweights advance	24-02-25	RE

Chart Chugai Pharmaceutical Co., Ltd

Duration

Period

4519: Dynamic Chart

Company Profile

Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers, bones and joints diseases treatment, and kidney diseases. Net sales are distributed geographically as follows: Japan (57.3%), Switzerland (39.9%) and other (2,8%).

Employees

7,604

Sector

Pharmaceuticals

Calendar

2025-01-30 - Q4 2024 Earnings Release

More about the company